PPARGC1A and melanoma: However, our investigation demonstrates that CDK4/6 inhibition does not significantly alter the effects of BRAF and MEK inhibitors on either glycolysis or OXPHOS in melanoma cells, nor does it significantly alter the expression of the MITF-PGC1A-mitochondrial metabolism pathway.